This growth is mainly driven by the following factors:
- A rise in cigarette smoking, which would boost the tobacco and nicotine addiction treatment market
- Production of new addiction treatment drugs, therapies and technologies
- Higher rates of substance abuse
- Growing awareness and acceptance of addiction as a disease requiring treatment
- Increased government investment in addiction treatment services
- Wider insurance coverage for treatment
- Reduced stigma of addiction
- Telemedicine becoming more common
- Data analytics to improve treatment outcomes
- Peer support programs becoming more popular
- Behavioral health services being used more often alongside addiction treatment
- Holistic and tailored treatment approaches becoming more common
Companies profiled in the report producing addiction treatment drugs include:
- Alkermes
- Cipla
- GlaxoSmithKline
- Pfizer
- Mallinckrodt
- Hikma Pharmaceuticals
- Orexo AB
- Titan Pharmaceuticals
- Teva Pharmaceutical Industries
- Indivor
The report also notes that North America is the most attractive area for growth in the addiction treatment market, according to a March 20 press release.
At the Becker's Fall Behavioral Health Summit, taking place October 20–22 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
